These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 15518364

  • 1. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
    Siddiqui K, Abbas F, Biyabani SR, Ather MH, Talati J.
    J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.
    Urol Int; 2005 Sep; 75(3):217-21. PubMed ID: 16215308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y.
    Urol Int; 2005 Sep; 75(1):43-9. PubMed ID: 16037707
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY, Chi KN.
    Can J Urol; 2006 Dec 01; 13(6):3335-9. PubMed ID: 17187697
    [Abstract] [Full Text] [Related]

  • 17. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H, Sakamoto T, Kiyama S, Ubai T, Kotake Y, Inamoto T, Takahara K, Nishimura Y, Segawa N, Katsuoka Y.
    Am J Clin Oncol; 2008 Apr 01; 31(2):188-94. PubMed ID: 18391605
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L.
    J Clin Oncol; 2005 Jan 20; 23(3):455-60. PubMed ID: 15659491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.